News for Livzon Pharmaceutical Group Inc (LP6.BE)

Published at

Jan 7, 2021 2:01 PM

by thestreet.com

neutral

neutral

CARISMA Therapeutics Completes Series B Funding For $47 Million To Advance Development Of Novel CAR-Macrophage Immunotherapies

PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative

LP6.F LP6.BE 1513.HK 000513.SZ

Read more →
Published at

Jan 7, 2021 1:00 AM

by vcaonline.com

neutral

neutral

Venture Capital Access Online

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies PHILADELPHIA, January 7, 2021-- C...

LP6.F LP6.BE 1513.HK 000513.SZ

Read more →